Disposition of 44000 shares by Sarah Nemec of Bolt Biotherapeutics at 3.08 subject to Rule 16b-3
BOLT Stock | USD 0.53 0.04 7.02% |
Slightly above 61% of Bolt Biotherapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Bolt Biotherapeutics suggests that many traders are alarmed. Bolt Biotherapeutics' investing sentiment can be driven by a variety of factors including economic data, Bolt Biotherapeutics' earnings reports, geopolitical events, and overall market trends.
Bolt |
Filed transaction by Bolt Biotherapeutics Officer Principal Accounting Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Bolt Biotherapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Bolt Biotherapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Bolt Biotherapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Bolt Biotherapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Bolt Biotherapeutics Fundamental Analysis
We analyze Bolt Biotherapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bolt Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bolt Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Bolt Biotherapeutics is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Bolt Biotherapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Bolt Biotherapeutics stock to make a market-neutral strategy. Peer analysis of Bolt Biotherapeutics could also be used in its relative valuation, which is a method of valuing Bolt Biotherapeutics by comparing valuation metrics with similar companies.
Peers
Bolt Biotherapeutics Related Equities
ASMB | Assembly Biosciences | 1.86 | ||||
NUVB | Nuvation Bio | 1.87 | ||||
ACHL | Achilles Therapeutics | 2.94 | ||||
NXTC | NextCure | 3.54 | ||||
CTMX | CytomX Therapeutics | 5.08 | ||||
SPRO | Spero Therapeutics | 5.17 | ||||
TIL | Instil Bio | 7.67 |
Additional Tools for Bolt Stock Analysis
When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.